We are live on ! Find out more
AGRX

Agile Therapeutics
AGRX

Delisted

AGRX was delisted on the 25th of March, 2024.

Back to rankings

62 hedge funds and large institutions have $133M invested in Agile Therapeutics in 2016 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 16 increasing their positions, 11 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,100% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 1

45% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 11

22% more funds holding

Funds holding: 51 → 62 (+11)

20% less capital invested

Capital invested by funds: $167M → $133M (-$33.8M)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
62
Holders Change
+11
Holders Change %
+21.57%
% of All Funds
1.55%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.07%
New
12
Increased
16
Reduced
11
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CC
Caxton Corporation
New Jersey
+$2.45M
2
EAM
EverPoint Asset Management
Connecticut
+$1.4M
3
DM
Deerfield Management
New York
+$1.04M
4
PVI
Pura Vida Investments
New York
+$981K
5
HCMT
Highland Capital Management (Texas)
Texas
+$827K

Top Sellers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
-$3.55M
2
AC
Aisling Capital
New York
-$3.31M
3
PA
Perceptive Advisors
New York
-$2.51M
4
GIM
Granahan Investment Management
Massachusetts
-$1.91M
5
JGC
J. Goldman & Co
New York
-$1.04M
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
26
Renaissance Technologies
New York
$365K +$308K +22 +220%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$361K +$14K +1 +3%
HLA
28
Hamilton Lane Advisors
Pennsylvania
$308K -$14K -1 -4%
FLAM
29
First Light Asset Management
Minnesota
$264K +$56K +4 +21%
BIM
30
BlackRock Investment Management
Delaware
$260K – – –
Morgan Stanley
31
Morgan Stanley
New York
$238K +$238K +17 +425%
TCIM
32
TIAA CREF Investment Management
New York
$228K -$14K -1 -5%
TC
33
TFS Capital
Pennsylvania
$223K +$210K +15 +300%
JGC
34
J. Goldman & Co
New York
$205K -$1.04M -74 -80%
RHJA
35
Rice Hall James & Associates
California
$176K +$28K +2 +15%
COPPSERS
36
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$175K – – –
AP
37
AlpInvest Partners
Netherlands
$158K – – –
T. Rowe Price Associates
38
T. Rowe Price Associates
Maryland
$158K – – –
California State Teachers Retirement System (CalSTRS)
39
California State Teachers Retirement System (CalSTRS)
California
$156K – – –
Susquehanna International Group
40
Susquehanna International Group
Pennsylvania
$121K +$154K +11 New
TA
41
Teachers Advisors
New York
$111K – – –
JP Morgan Chase
42
JP Morgan Chase
New York
$106K +$126K +9 New
OM
43
Opaleye Management
Massachusetts
$85K +$112K +8 New
Charles Schwab
44
Charles Schwab
California
$77K – – –
PA
45
Pinnacle Associates
New York
$57K -$280K -20 -80%
PWMAG
46
Pinnacle Wealth Management Advisory Group
New Jersey
$57K -$280K -20 -80%
New York State Common Retirement Fund
47
New York State Common Retirement Fund
New York
$54K – – –
GT
48
Glenmede Trust
Pennsylvania
$53K – – –
NFA
49
Nationwide Fund Advisors
Ohio
$45K – – –
AIG
50
American International Group
New York
$44K – – –
1
2
3

AGRX Hedge Fund Activity: Q4 2016 in Review

62 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q4 2016, worth a combined $133M — down 20% from $167M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new AGRX positions and 1 closed out — a net gain of 11 holders — while 16 added to existing stakes and 11 trimmed.

The largest buyer was Caxton Corporation, adding an estimated $2.45M. The largest seller was Vivo Capital, cutting an estimated $3.55M.

  • 62 institutional investors held Agile Therapeutics (AGRX) as of Q4 2016, up from 51 in Q3 2016.
  • Funds reported $133M of Agile Therapeutics stock for Q4 2016, down 20% quarter-over-quarter.
  • 12 funds opened new Agile Therapeutics positions in Q4 2016 and 1 closed out, a net change of +11 holders.
  • The largest Agile Therapeutics buyer in Q4 2016 was Caxton Corporation, an estimated $2.45M added.
  • The largest Agile Therapeutics seller in Q4 2016 was Vivo Capital, an estimated $3.55M sold.

Based on aggregated 13F filings for Q4 2016.